The first step of a successful viral infection is virus attachment to a cell-surface receptor. The recent discovery that histo-blood group antigens (HBGAs) may be potential rotavirus (RV) receptors has significantly improved our understanding of RV epidemiology, disease burden, and pathogenesis. However, RVs exhibit significant diversity and are capable of causing disease in many different populations and animal species, making it difficult to develop broadly effective vaccines against RVs. As examples, the P[6] and P[11] RVs recognize HBGA precursors or intermediate products and revealed unique age-specific host ranges in neonates and young infants, further complicating strategies for safe and effective vaccine delivery. In addition, both P[6] and P[11] RVs are commonly found in developing countries, likely due to a human genetic predisposition for unique HBGA types (Lewis negative) and zoonotic transmission of these two genotypes in rural areas, and may require a cocktail vaccine including P[6] and/or P[11] RVs to confer broad protection to children. In this application, we will perform field surveillance of RV infection in South African children to better understand the high prevalence of P[6] RVs, among other circulating genotypes, and guide improvement of current RV vaccines and/or development of new vaccines against RVs.
Two aims will be fulfilled: First, we will evaluate circulating RV strains and their HBGA binding patterns in children to verify the HBGA-specific host ranges of major circulating RV P types in African children. A two-year surveillance of RV gastroenteritis in neonates and young infants will be performed at two sentinel sites. Special attention will be paid to the roles of specific HBGAs, such as the type 1 chain precursors, during P[6] RV infection in children. We will also assess the antigenic relatedness among major circulating human RVs and compare them to the current RV vaccine strains to identify additional potential targets for future vaccines. Second, we will study the age-specific tropism of P[6] and P[11] RVs in neonates and young infants. The age-windows for infection with specific RV P types will be determined through the RV surveillance in Aim 1. A cohort with monthly saliva samples from neonates and young infants from birth to one year of age will be collected to define the age-windows of expression for specific HBGA receptors that bind P[6] and P[11] RVs. Knowledge gained through these studies is valuable to design a vaccination program for safe and effective delivery of these vaccine strains. Finally, to advance the next generation of RV vaccines, we will study the biological properties and usefulness of a live, attenuated P[6] RV, developed in our group, as a potential candidate in a new cocktail vaccine against RVs.

Public Health Relevance

Rotaviruses are diverse in causing disease within different populations, which is determined by the host HBGAs. This R21 application will study the host ranges, strain variations, and disease burden of RVs in African children to understand the mechanisms behind the high prevalence and age-specific host ranges of P[6] and P[11] RVs in children living in developing countries. The knowledge gained will be used to improve current RV vaccines and/or develop new, safer, and more effective vaccines against RVs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI130631-01
Application #
9298176
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
Alarcon, Rodolfo M
Project Start
2017-02-15
Project End
2019-01-31
Budget Start
2017-02-15
Budget End
2018-01-31
Support Year
1
Fiscal Year
2017
Total Cost
$188,360
Indirect Cost
$59,920
Name
Cincinnati Children's Hospital Medical Center
Department
Type
Independent Hospitals
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229